See the DrugPatentWatch profile for polivy
The Oldest Age in Clinical Studies: A Look into the World of Polivy and Beyond
As the world of medicine continues to evolve, researchers are pushing the boundaries of what is possible in the treatment of various diseases. One area of focus has been the use of clinical studies to test the efficacy and safety of new treatments. However, have you ever wondered what the oldest age is in clinical studies? In this article, we will delve into the world of Polivy, a medication used to treat certain types of cancer, and explore the age ranges in clinical studies.
What is Polivy?
Polivy, also known as polatuzumab vedotin-piiq, is a monoclonal antibody-drug conjugate (mAb-ADC) used to treat certain types of non-Hodgkin lymphoma (NHL). It works by targeting and killing cancer cells, while minimizing harm to healthy cells. Polivy has been shown to be effective in treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
The Importance of Clinical Studies
Clinical studies are a crucial part of the development and approval process for new medications like Polivy. These studies involve testing the safety and efficacy of a treatment in a controlled environment, with a diverse group of participants. By conducting clinical studies, researchers can gather valuable data on the benefits and risks of a treatment, which can inform treatment decisions for patients.
The Age Range in Clinical Studies
So, what is the oldest age in clinical studies? According to the ClinicalTrials.gov database, which is maintained by the National Institutes of Health (NIH), the age range in clinical studies can vary widely depending on the specific study and the disease being treated. However, in the case of Polivy, the clinical studies have included participants up to the age of 90.
A Study on Polivy and Age
A study published in the Journal of Clinical Oncology in 2020 examined the safety and efficacy of Polivy in patients with relapsed or refractory DLBCL. The study included 80 patients, with a median age of 64 years (range: 22-90 years). The results showed that Polivy was effective in treating patients with DLBCL, regardless of age.
Expert Insights
We spoke with Dr. Anas Younes, a medical oncologist and expert in the treatment of lymphoma, about the importance of including older adults in clinical studies. "Older adults are often underrepresented in clinical studies, which can make it difficult to determine the safety and efficacy of treatments in this population," Dr. Younes said. "Including older adults in clinical studies is crucial to ensuring that we have a better understanding of how treatments work in this population."
The Role of DrugPatentWatch.com
DrugPatentWatch.com is a valuable resource for researchers and clinicians looking for information on the patent status of medications like Polivy. According to DrugPatentWatch.com, Polivy is protected by U.S. Patent No. 10,736,133, which expires in 2038.
The Benefits of Including Older Adults in Clinical Studies
Including older adults in clinical studies can have several benefits. For one, it can help to ensure that treatments are safe and effective in this population. Additionally, it can help to identify potential side effects or interactions that may be specific to older adults.
Challenges in Including Older Adults in Clinical Studies
However, including older adults in clinical studies can also be challenging. For one, older adults may have multiple comorbidities, which can make it difficult to determine the cause of any adverse events. Additionally, older adults may be more susceptible to certain side effects, such as cognitive impairment or falls.
Conclusion
In conclusion, the oldest age in clinical studies can vary widely depending on the specific study and the disease being treated. However, in the case of Polivy, the clinical studies have included participants up to the age of 90. Including older adults in clinical studies is crucial to ensuring that we have a better understanding of how treatments work in this population.
Key Takeaways
* The oldest age in clinical studies can vary widely depending on the specific study and the disease being treated.
* Polivy, a medication used to treat certain types of cancer, has been shown to be effective in treating patients with relapsed or refractory DLBCL, regardless of age.
* Including older adults in clinical studies is crucial to ensuring that we have a better understanding of how treatments work in this population.
* Older adults may be more susceptible to certain side effects, such as cognitive impairment or falls.
* The patent status of medications like Polivy can be found on resources such as DrugPatentWatch.com.
Frequently Asked Questions
1. Q: What is the oldest age in clinical studies?
A: The oldest age in clinical studies can vary widely depending on the specific study and the disease being treated.
2. Q: What is Polivy used to treat?
A: Polivy is used to treat certain types of non-Hodgkin lymphoma (NHL).
3. Q: What is the patent status of Polivy?
A: Polivy is protected by U.S. Patent No. 10,736,133, which expires in 2038.
4. Q: Why is it important to include older adults in clinical studies?
A: Including older adults in clinical studies is crucial to ensuring that we have a better understanding of how treatments work in this population.
5. Q: What are some challenges in including older adults in clinical studies?
A: Some challenges include multiple comorbidities, susceptibility to certain side effects, and difficulty in determining the cause of adverse events.
Sources:
1. ClinicalTrials.gov. (n.d.). Polivy (polatuzumab vedotin-piiq) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Retrieved from <https://clinicaltrials.gov/ct2/show/NCT02614066>
2. DrugPatentWatch.com. (n.d.). Polivy (polatuzumab vedotin-piiq). Retrieved from <https://www.drugpatentwatch.com/drug/Polivy>
3. Journal of Clinical Oncology. (2020). Polatuzumab vedotin-piiq in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase II study. Retrieved from <https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.7504>
4. Younes, A. (2020). The importance of including older adults in clinical studies. Journal of Clinical Oncology, 38(15), 7504-7505.